Fujita H, Yoshiyama M, Takeuchi K, Omura T, Yamagishi H, Iwao H, Miura K, Yoshikawa J
First Department of Internal Medicine, Osaka City University Medical School, Japan.
Jpn J Pharmacol. 1998 Oct;78(2):229-32. doi: 10.1254/jjp.78.229.
This study was designed to assess the effect of a nonpeptide vasopressin V1-receptor antagonist, OPC-21268, and a vasopressin V2-receptor antagonist, OPC-31260, on hemodynamics in the early phase and the late phase after myocardial infarction in rats. In the early phase, OPC-21268 (30 mg/kg/day) or OPC-31260 (30 mg/kg/day) was orally administered from day 1 to day 5 after the operation; and hemodynamics were measured at day 5, in the late phase from 10 weeks to 11 weeks and measured at the end of 11 weeks. In the early phase, OPC-21268 reduced the left ventricular end-diastolic pressure (LVEDP) concomitantly with the reduction in systemic blood pressure, but did not change LVEDP in the late phase. OPC-31260 reduced LVEDP and central venous pressure in both phases. OPC-21268 improved hemodynamics only in the early phase and OPC-31260 improved it in both phases.
本研究旨在评估非肽类血管加压素V1受体拮抗剂OPC - 21268和血管加压素V2受体拮抗剂OPC - 31260对大鼠心肌梗死后早期和晚期血流动力学的影响。在早期，于术后第1天至第5天口服给予OPC - 21268（30毫克/千克/天）或OPC - 31260（30毫克/千克/天）；在第5天测量血流动力学，晚期为第10周龄至第11周龄，并在第11周龄末测量血流动力学。在早期，OPC - 21268在降低体循环血压的同时降低了左心室舒张末期压力（LVEDP），但在晚期并未改变LVEDP。OPC - 31260在两个阶段均降低了LVEDP和中心静脉压。OPC - 21268仅在早期改善了血流动力学，而OPC - 31260在两个阶段均改善了血流动力学。
